aluxum Truist has downgraded Incyte ( NASDAQ: INCY ) to hold from buy citing the upcoming loss of exclusivity in 2028 of its key drug Jakafi (ruxolitinib). The also lowered its price target to $74 from $83 (~11% upside based on Sept. 17 closing price).
.
